
Avivomed
Developing and commercializing next generation neuromodulaton technology platforms to treat patients suffering from chronic diseases.
Employees
Enterprise value
$128—192m
Developing and commercializing next generation neuromodulaton technology platforms to treat patients suffering from chronic diseases.